According to Google DeepMind on Twitter, experts @_rebecca_paul and @maxjaderberg from Isomorphic Labs discussed how AI agents are revolutionizing drug discovery by enabling human experts to efficiently explore vast molecular spaces. Their conversation with @fryrsquared emphasized that AI does not replace human intuition but augments the ability to identify promising compounds, drastically reducing time and cost in early-stage pharmaceutical research (source: Google DeepMind, June 11, 2025). The integration of AI-driven molecular exploration opens significant business opportunities for biotech firms and pharmaceutical companies seeking to accelerate R&D pipelines and gain competitive advantages in drug development.